Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy
Related Experiment Video
Updated: Jun 13, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Vishnu Vijay Vijayan1, Preethi Gopalakrishnan Nair1,2, Shashi Gujar1,2,3,4,5
1Department of Pathology, Dalhousie University, Halifax, Canada.
Abstract:
CD38, a multifunctional enzyme involved in NAD+ catabolism, is hypothesized to act as a metabolic checkpoint for antitumor CD8 T cells. A recent study discovered that, apart from its direct metabolic mechanisms, CD38-mediated RyR2-AKT-TCF1 signaling regulates responsiveness to anti-PD1 cancer therapy at the molecular level. These findings advocate multiprong CD38 targeting to overcome resistance to immune checkpoint blockade therapy.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...

